NASDAQ:ATRA

Atara Biotherapeutics (ATRA) Stock Price, News & Analysis

Atara Biotherapeutics logo
$6.77 +0.27 (+4.15%)
As of 04:00 PM Eastern

About Atara Biotherapeutics Stock (NASDAQ:ATRA)

Advanced

Key Stats

Today's Range
$6.47
▼
$6.92
50-Day Range
$6.40
▼
$10.11
52-Week Range
$3.92
▼
$19.15
Volume
15,314 shs
Average Volume
25,609 shs
Market Capitalization
$68.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50
Consensus Rating
Moderate Buy

Company Overview

Atara Biotherapeutics is a biotechnology company focused on developing allogeneic T-cell immunotherapies for cancer and other serious diseases. Founded in 2012 and based in Thousand Oaks, California, the company’s approach uses immune cells from donors rather than cells collected from each individual patient.

Its lead therapy, tabelecleucel, is an Epstein-Barr virus (EBV)-specific T-cell treatment for EBV-positive post-transplant lymphoproliferative disease, a rare complication that can occur after an organ or stem-cell transplant. The therapy is marketed in Europe under the name Ebvallo through a partnership with Pierre Fabre; it received conditional marketing authorization from the European Commission in 2022.

Atara has also worked on other engineered and virus-specific T-cell therapies for oncology and autoimmune indications. Its research and commercial activities have included collaborations with pharmaceutical partners, while its pipeline and programs may change as development priorities evolve.

AI Generated. May Contain Errors.

Atara Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

ATRA MarketRank™: 
3.09649478955 of 5 stars

Atara Biotherapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 659th out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Atara Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Atara Biotherapeutics has a consensus price target of $9.50, representing about 40.3% upside from its current price of $6.77.

  • Amount of Analyst Coverage

    Atara Biotherapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Atara Biotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Atara Biotherapeutics are expected to grow in the coming year, from ($0.22) to $1.38 per share.

  • Percentage of Shares Shorted

    5.03% of the float of Atara Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Atara Biotherapeutics has a short interest ratio ("days to cover") of 13.43, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Atara Biotherapeutics has recently decreased by 15.31%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Atara Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    Atara Biotherapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Atara Biotherapeutics has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Atara Biotherapeutics this week, compared to 5 articles on an average week.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $960,627.00 in company stock, which represents 1.3925% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Atara Biotherapeutics insiders have bought 2,440.18% more of their company's stock than they have sold. Specifically, they have bought $999,994.00 in company stock and sold $39,367.00 in company stock.

  • Percentage Held by Insiders

    41.20% of the stock of Atara Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    70.90% of the stock of Atara Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Atara Biotherapeutics' insider trading history.
Receive ATRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ATRA Stock News Headlines

You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
Atara Resubmits Tabelecleucel BLA To FDA
See More Headlines

ATRA Stock Analysis - Frequently Asked Questions

Atara Biotherapeutics' stock was trading at $18.09 at the beginning of 2026. Since then, ATRA stock has decreased by 62.6% and is now trading at $6.77.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) released its quarterly earnings results on Tuesday, November, 10th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by $0.02. The biotechnology company earned $1.22 million during the quarter, compared to analyst estimates of $800 thousand.

Shares of Atara Biotherapeutics reverse split on the morning of Thursday, June 20th 2024.The 1-25 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Atara Biotherapeutics (ATRA) raised $75 million in an IPO on Thursday, October 16th 2014. The company issued 5,000,000 shares at $14.00-$16.00 per share.

Top institutional shareholders of Atara Biotherapeutics include State Street Corp (0.26%) and Empowered Funds LLC (0.14%). Insiders that own company stock include Innovation Ltd Panacea, Brian N Cherry, Anhco Nguyen, Pascal Touchon, Eric J Hyllengren, Yanina Grant-Huerta and Jill Henrich.
View institutional ownership trends
.

Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Atara Biotherapeutics investors own include Allogene Therapeutics (ALLO), CRISPR Therapeutics (CRSP), Micron Technology (MU), AT&T (T), NVIDIA (NVDA), Tesla (TSLA) and Alibaba Group (BABA).

Company Calendar

Last Earnings
11/10/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ATRA
CIK
1604464
Fax
N/A
Employees
10
Year Founded
2012

Price Target and Rating

High Price Target
$13.00
Low Price Target
$6.00
Potential Upside/Downside
+40.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
4.91
P/E Growth
N/A
Net Income
$32.69 million
Net Margins
-368.58%
Pretax Margin
-368.55%
Return on Equity
N/A
Return on Assets
-73.19%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.72
Quick Ratio
1.72

Sales & Book Value

Annual Sales
$120.77 million
Price / Sales
0.57
Cash Flow
$5.13 per share
Price / Cash Flow
1.32
Book Value
($3.72) per share
Price / Book
-1.82

Miscellaneous

Outstanding Shares
10,190,000
Free Float
5,991,000
Market Cap
$68.99 million
Optionable
No Data
Beta
0.28

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:ATRA) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners